In conclusion, we revealed that NUF2, CDCA3, and KIF14 are novel m6A-modified biomarkers for ccRCC, which might provide a new perspective for clinical diagnose and treatment. The gene discussed is NUF2; the disease is nonpapillary renal cell carcinoma.